Endogenous Human Peptides & Exotic Animal Peptides
The peptides your body already makes — and the strange, exceptional peptides found only in other species.
A solo narrator walks you through the key takeaways of "Endogenous Human Peptides & Exotic Animal Peptides". First generation takes ~10–20 s, then it's cached for everyone.
What's covered
Click any topic to expand a deeper drill-down with mechanism, key references, and a take-home summary.
By the end of this module you will be able to
- L01Map the major families of endogenous human peptides to their tissues of origin and primary receptors.
- L02Explain why ~30 of the top-200 prescription drugs are peptides or peptide-derived, tracing several back to a specific endogenous human peptide.
- L03Identify at least four FDA-approved drugs whose lead structure was discovered in a non-human animal.
- L04Distinguish between an endogenous peptide (produced by human cells), a synthetic analog (engineered for stability), and a xenopeptide (sourced from another species).
- L05Discuss responsibly the limits of extrapolating from exotic-animal physiology (tardigrade, naked mole-rat, hibernating bear) to human therapeutics.
What you should walk away believing
Click any takeaway to open a full AI-generated lesson with mechanism, examples, evidence grading, counseling scripts, pearls, references, and a self-check.
What this means for you
Your body makes hundreds of its own peptides — short chains of amino acids — that run digestion, blood sugar, blood pressure, sleep, mood, immunity, and reproduction. Many modern medications are slightly modified copies of these natural peptides: Ozempic mimics a gut hormone called GLP-1, vasopressin medications mimic a brain hormone, and parathyroid hormone treatments mimic a bone-regulating hormone. Other peptide drugs come from surprising places — Gila monster saliva, cone snail venom, and snake venom have all produced approved medicines. Animals like tardigrades, naked mole-rats, and hibernating bears are being studied for their unusual peptides, but those are still research, not treatments.
Treat the human peptidome as the foundation for the entire field: every major therapeutic peptide class either replaces, mimics, or blocks an endogenous signaling peptide. Anchor patient education in this — semaglutide is a long-acting GLP-1 analog, octreotide is a somatostatin analog, leuprolide is a GnRH superagonist, desmopressin is a V2-selective vasopressin analog, teriparatide is recombinant PTH(1-34), calcitonin-salmon exploits a higher-affinity non-human ortholog. Animal-derived peptide drugs (exenatide, ziconotide, captopril ancestry, eptifibatide, tirofiban scaffold) illustrate venom-as-pharmacy. Frontier biology in tardigrades (Dsup), naked mole-rats (HMW-hyaluronan, hypoxia tolerance), bears (urea recycling, lean-mass preservation in torpor), and Antarctic icefish (antifreeze glycopeptides) is biologically real but clinically unproven — useful framing when patients see these in popular media.
Consider three taxonomies in parallel. (1) By tissue: hypothalamic releasing peptides (TRH, GnRH, CRH, GHRH), posterior pituitary (AVP, OT), pancreatic islet (insulin, glucagon, amylin, SST, PP), enteroendocrine (GLP-1/2, GIP, PYY, CCK, ghrelin, motilin, secretin, neurotensin), cardiac (ANP/BNP/CNP), renal (urodilatin), adipose (leptin, adiponectin), bone (PTH, calcitonin, osteocalcin), immune (defensins, LL-37, hepcidin), CNS (orexin/hypocretin, MCH, NPY, AgRP, POMC-derived α-MSH/β-endorphin, substance P, CGRP, enkephalins, dynorphin). (2) By receptor superfamily: most signal through Class A or Class B GPCRs (incretins, glucagon, PTH, secretin, CRH, GHRH all Class B). (3) By drug-discovery origin: replacement (insulin, PTH, vasopressin), agonist (GLP-1 RAs, GnRH agonists), antagonist (CGRP-blocking gepants/antibodies, orexin antagonists for insomnia), and venom-derived scaffolds (exenatide, ziconotide, ACE-inhibitor ancestry from BPP-9a). Exotic-species frontier: tardigrade Dsup is a DNA-shielding intrinsically-disordered protein with in-vitro radioprotective activity; naked mole-rat resistance to cancer and hypoxia involves HMW-HA and unique tissue-protective signaling rather than a single drug-like peptide; bear hibernation work (HP-20c, BHB, and hibernation-specific protein complexes) is mechanistically interesting for muscle and bone preservation but not yet a clinical pipeline; Antarctic notothenioid antifreeze glycopeptides are explored for organ-preservation fluids, not systemic therapy.
If a peptide is found in nature — in your body or in an animal — it must be safe and 'physiologic' to use as a drug.
Endogenous peptides are tightly regulated in time, location, concentration, and degradation. Giving a stable analog at supra-physiologic levels is exactly what makes it a drug — and exactly why side effects appear. Calcitonin-salmon causes nausea and rare malignancy signals; chronic GLP-1 RA exposure causes the GI and gallbladder profile we see clinically; vasopressin analogs cause hyponatremia. 'Natural' is not a safety claim.
From Gila monster spit to a $40B drug class
A med student asks why GLP-1 receptor agonists are so effective at suppressing appetite when 'natural' GLP-1 lasts under 2 minutes in plasma. You walk her through the discovery of exendin-4 in the saliva of Heloderma suspectum, the 53% sequence identity with human GLP-1, the DPP-4 resistance, and the path from exenatide (2005) to semaglutide and tirzepatide.
What is the single most important pharmacologic lesson from the exendin-4 → exenatide → semaglutide arc?
What the data say
Test yourself
Lock it in — review what's due
Key terms & abbreviations
- Endogenous peptide
- A peptide produced by human cells as part of normal physiology (e.g., insulin, GLP-1, vasopressin, β-endorphin).
- Xenopeptide
- A peptide derived from a non-human species, often used as the starting structure for a human drug (e.g., exendin-4 from Gila monster, ω-conotoxin from cone snail).
- Analog
- A peptide deliberately modified from a parent sequence to improve potency, selectivity, or pharmacokinetics (e.g., octreotide vs somatostatin).
- Defensin
- Cysteine-rich cationic antimicrobial peptide of innate immunity. α-defensins are mainly neutrophil-derived; β-defensins are epithelial.
- Cathelicidin (LL-37)
- 37-residue C-terminal antimicrobial peptide of human cathelicidin precursor hCAP-18; broad antimicrobial and immunomodulatory activity.
- Hepcidin
- 25-aa hepatic peptide that binds ferroportin and is the master regulator of systemic iron.
- Orexin / hypocretin
- Hypothalamic neuropeptides regulating wakefulness; loss of orexin neurons causes type-1 narcolepsy.
- Dsup (damage suppressor)
- Tardigrade-specific intrinsically-disordered protein that associates with chromatin and reduces DNA damage from radiation and ROS in vitro.
- Antifreeze glycopeptide (AFGP)
- Glycopeptides from notothenioid Antarctic fish that depress the freezing point of body fluids by binding ice nuclei.
Optional deeper dive
- Eng J et al. — Isolation and characterization of exendin-4 from Heloderma suspectum venom — J Biol Chem 1992; 267:7402–7405
- Olivera BM, Cruz LJ — Conotoxins, in retrospect — Toxicon 2001; 39:7–14
- Cushman DW, Ondetti MA — History of the design of captopril and related ACE inhibitors — Hypertension 1991; 17:589–592
- Hashimoto T et al. — Extremotolerant tardigrade genome and Dsup radioprotection — Nature Communications 2016; 7:12808
- Tian X et al. — High-molecular-weight hyaluronan mediates the cancer resistance of the naked mole rat — Nature 2013; 499:346–349
- Lin DC et al. — Hibernating bears and skeletal muscle preservation — Journal of Experimental Biology / multiple
- Ganz T — Hepcidin and iron regulation, 10 years later — Blood 2011; 117:4425–4433